Please enable Javascript
Dustin Samples
Articles by Dustin Samples
Topical Frankincense Did Not Relieve Chemotherapy-Related Fatigue
Dustin Samples
Treatment
|
May 22, 2023
The results did not support anecdotal reports that the essential oil relieves cancer-related symptoms.
Read More
New Model Proposed for Maintenance of GVHD
Dustin Samples
GVHD
|
May 17, 2023
In one murine study, donor T cells appeared to maintain a progenitor-like population in GVHD-affected tissue.
Read More
Erythema Better Predictor of Death in Chronic GVHD Than Skin Score
Dustin Samples
GVHD
|
May 17, 2023
Erythema body surface area kept its total prognostic information on NRM and OS longer than the NIH scoring system.
Read More
GVHD Alliance: Awareness and Support Website for Patients
Dustin Samples
Patient Voice
|
May 11, 2023
The GVHD Alliance is thorough and logical in its presentation of material, and it offers a search by symptom option.
Read More
Sustained MRD-Negativity Is Associated With Improved Outcomes in Relapsed/Refractory MM
Dustin Samples
Conferences
|
May 2, 2023
Patients who remained MRD-negative for ≥12 months had better duration of response and progression-free survival.
Read More
Clinical Considerations and Patient Counseling for Those Receiving Sacituzumab Govitecan-hziy
Dustin Samples
Treatment
|
April 28, 2023
Linda Buck led a information session on sacituzumab govitecan-hziy at ONS 2023.
Read More
FDA Announces Changes to PI3Ki Accelerated Approval Process
Dustin Samples
Conferences
|
April 27, 2023
Accelerated approvals will no longer be granted based on overall response rates in single-arm trials.
Read More
Enoblituzumab Performs Well in Phase 2 Trial of Prostate Cancer Patients
Dustin Samples
GU Cancer
|
April 24, 2023
The novel monoclonal antibody targeted B7-H3 with high success and low incidence of adverse events.
Read More
GVHD Prophylaxis With Post-transplant Cyclophosphamide and Immunosuppressants in Haplo-HSCT
Dustin Samples
GVHD
|
April 19, 2023
A single-center study demonstrated good results with the trio of PT-Cy, tacrolimus, and low-dose anti-thymocyte globulin.
Read More
Three Biologic-Based Therapies Offer Promise for Less Toxic GVHD Prophylaxis
Dustin Samples
GVHD
|
April 19, 2023
Exosomes, T regulatory cells, and myeloid-derived-suppressor-cells could be the future of GVHD prevention.
Read More
A Focused Hub of Resources for Patients With Cancer
Dustin Samples
Patient Voice
|
April 13, 2023
It might seem counterintuitive, but the “less is more” approach may be best when providing cancer resources.
Read More
Exercise Alone Is Insufficient Pain Management for Patients With Cancer
Dustin Samples
Patient Voice
|
April 13, 2023
Though studies on the subject are plentiful, there is a lack of evidence supporting exercise as an effective pain mitigator.
Read More
Patient Perceptions of the Nurse-Patient Relationship at End of Life
Dustin Samples
Patient Voice
|
April 13, 2023
Despite research suggesting deterioration in HCP-patient relationships at EOL, patients in one study did not feel abandoned.
Read More
Allostatic Load and Depression in Cancer Survivors
Dustin Samples
Patient Voice
|
April 13, 2023
Do the physiological effects of stress correlate with increased depression in adult cancer survivors?
Read More
Real-World Duration of Venetoclax Treatment Varied From Approved Dosing Schedule
Dustin Samples
Conferences
|
April 6, 2023
The approved dosing schedule for venetoclax is time-limited, but how many patients follow the schedule?
Read More
Origins and Underlying Mechanism of Sequential or Concurrent CLL/CML
Dustin Samples
Conferences
|
April 6, 2023
Though rare, CLL and CML sometimes occur sequentially or concurrently. But what is the mechanism behind the relationship?
Read More
Trial for Non-Melanoma Skin Cancer in Patients With CLL Now Enrolling
Dustin Samples
Conferences
|
April 6, 2023
In a currently enrolling trial, patients with CLL and NMSC will receive experimental treatment with nicotinamide.
Read More
Updated Treatment Guidelines for CLL/SLL
Dustin Samples
Conferences
|
April 6, 2023
Deborah Stephens, DO, presented the recommendations and algorithms for first-, second-, and third-line CLL/SLL therapy.
Read More
Oral Dysbiosis Associated With Increased Risk of Posttransplant Disease, GVHD
Dustin Samples
GVHD
|
March 29, 2023
Certain species were predictive of not only the occurrence of GVHD, but also the severity.
Read More
Pruritus in Cutaneous GVHD Is Both Underreported and Understudied
Dustin Samples
GVHD
|
March 29, 2023
Pruritus is considered a mild adverse event, but does it negatively affect quality of life?
Read More
Load More